Home › Medical › Cannabis and Post-Herpetic Neuralgia
⚐ Flag an error How this page was made
Also known as: PHN · postherpetic neuralgia

Cannabis and Post-Herpetic Neuralgia

Weak evidence for PHN specifically; modest effects seen only in related neuropathic pain conditions.

Automated fact-check pass
12 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Cannabis doesn't have proven efficacy specifically for PHN. The evidence mostly comes from other neuropathic pain conditions—HIV neuropathy, diabetic neuropathy, multiple sclerosis. Even there, the effect is modest and well behind gabapentin or pregabalin. PHN patients are typically older and on multiple medications, making drug interactions and cognitive side effects real concerns. Cannabis might be reasonable as an add-on if first-line treatments fail, but it's not a replacement.

Plain-language summary

Post-herpetic neuralgia (PHN) is persistent nerve pain that lingers after a shingles rash heals. It can last for months or years and is classified as neuropathic pain, meaning the nerves themselves are damaged or misfiring rather than responding to active tissue damage.

Standard treatments—gabapentin, pregabalin, tricyclic antidepressants, topical lidocaine, and topical capsaicin—help reduce pain in many patients, though complete pain relief is uncommon Strong evidence[1].

Cannabis is frequently discussed as an alternative. The honest picture: there is weak evidence that cannabinoids reduce chronic neuropathic pain in general Weak / limited, but no large, well-designed trial has tested cannabis specifically in PHN No data. Most claims about cannabis for PHN extrapolate from related conditions like HIV neuropathy, diabetic neuropathy, or multiple sclerosis pain.

⚠️ This article is not medical advice. PHN is a medical condition that interacts with other drugs—especially gabapentinoids and opioids—and with age-related health issues common in older adults. Decisions about starting, stopping, or combining cannabis with other treatments should be made with a clinician who knows your full medical history.

What probably works

Honestly: nothing in cannabis has strong evidence specifically for PHN. The closest we get is general chronic neuropathic pain.

Oral or oromucosal THC:CBD (nabiximols / Sativex)

This is a pharmaceutical-grade 1:1 THC:CBD spray that has been studied in randomized controlled trials for chronic neuropathic pain of mixed causes, including some patients with PHN-like presentations Weak / limited[2][3]. The Cochrane systematic review (2018) found that nabiximols modestly reduced neuropathic pain compared to placebo, with effect sizes typically 1–2 points on a 10-point pain scale Weak / limited[3]. The review included one trial (Nurmikko 2007) that enrolled some participants with PHN features, though not pure PHN populations. Important caveat: this is a prescription medication available in some countries but not all, and outcomes were modest.

Inhaled or vaporized THC-dominant cannabis

Small, short-duration randomized trials in HIV neuropathy and mixed neuropathy have shown pain reduction Weak / limited[4][5]. A 2013 trial of vaporized cannabis in HIV neuropathy (Wilsey et al.) found significant pain reduction compared to placebo Weak / limited[5]. Whether this effect generalizes to PHN is biologically plausible—the mechanisms of nerve damage overlap—but unproven No data.

---

That's the "probably works" tier, and even this is on shaky ground. The National Academies 2017 comprehensive review classified cannabis evidence in chronic pain as "substantial" but specifically noted that post-herpetic neuralgia was underrepresented in the trial literature Strong evidence[1].

What might work

CBD-dominant products for PHN

CBD has been shown in cell and animal models to modulate TRPV1 (a pain-sensing ion channel) and inflammatory signaling pathways implicated in neuropathic pain Weak / limited. However, human trial data in PHN is absent No data. Consumer CBD gummies and oils marketed for "nerve pain" have no PHN-specific evidence behind them. Do not mistake biological plausibility for clinical proof.

Topical cannabinoid creams applied to the affected skin area

One small open-label study reported benefit in facial PHN with a topical cannabinoid agonist Anecdote[6]. Other case series suggest possible benefit for localized neuropathic pain and associated itch, but no placebo-controlled PHN trial exists Anecdote. The evidence is preliminary and insufficient to guide clinical practice.

Cannabis for PHN-associated insomnia and mood

Chronic pain disrupts sleep and can trigger or worsen depression, both of which amplify pain perception. THC and CBD have weak evidence for sleep improvement in chronic pain populations generally Weak / limited. This is an indirect benefit—treating a consequence of pain, not the nerve pain itself—and should not be mistaken for PHN treatment.

CBD + standard care as an add-on

Theoretically interesting because CBD has fewer psychoactive side effects than THC and might be better tolerated in older adults. But no PHN-specific data exists No data, and the cognitive and interaction risks of THC are irrelevant if you're only considering pure CBD.

What doesn't work or has weak evidence

"Indica strains are better for nerve pain."

This is folklore. The indica/sativa labels do not reliably predict chemical composition or clinical effects Disputed[7]. See Cannabis Strain Labels and Effects for detail.

Specific cultivars marketed as "PHN strains" or "neuropathy strains"

No clinical data supports any specific cultivar for PHN. Dispensary recommendations here are marketing, not medicine No data.

CBD isolate gummies "curing" PHN

No evidence No data. Typical consumer CBD isolate products contain 10–25 mg of CBD per serving, well below the 200–600 mg/day doses used in neuropathic pain trials with pharmaceutical-grade products. Marketing claims often conflate animal studies with human efficacy.

Cannabis shortening or preventing PHN after shingles

No evidence cannabis affects the underlying viral infection or the nerve-damage process No data. Antivirals taken within 72 hours of shingles onset reduce PHN risk; the recombinant zoster vaccine (Shingrix) is highly effective at preventing shingles and PHN in older adults Strong evidence[8]. These are the interventions with proven preventive benefit.

What we don't know

Comparison with standard treatments

First-line treatments for PHN have stronger, more specific evidence than cannabis:

TreatmentEvidence tierTypical effectNotes
GabapentinStrong evidence[1][11]~30–50% pain reduction in ~1/3 of patientsRCT evidence, established guidelines; common side effects include dizziness, sedation
PregabalinStrong evidence[1][11]~30–50% pain reduction in ~1/3 of patientsSimilar to gabapentin; approved by FDA specifically for PHN
Tricyclic antidepressants (nortriptyline, amitriptyline)Strong evidence[1][11]~30–40% pain reductionLong-established; anticholinergic side effects limit use in older adults
Topical lidocaine 5% patchStrong evidence[11]Effective for localized PHNMinimal systemic side effects; applied directly to affected skin
Topical capsaicin 8% patchStrong evidence[11]Weeks of relief from single applicationFDA approved for localized neuropathic pain; initial burning sensation
Cannabis (THC:CBD)Weak / limited[3]1–2 point reduction on 10-point scale in general neuropathic painNo PHN-specific trial; modest effect; cognitive and interaction risks in older adults

Realistic positioning: Cannabis is not a replacement for first-line therapy in PHN. It occupies a niche as a reasonable add-on or alternative to consider when first-line treatments have failed or caused intolerable side effects—the same niche it holds in most chronic pain management guidelines Strong evidence[1].

Risks and practical considerations

PHN patients tend to be older, often on multiple medications, and frequently have cardiovascular or neurological comorbidities. Specific risks:

Cognitive and fall risks

THC impairs attention, processing speed, and balance—particularly concerning in older adults Strong evidence[9]. Falls are a major cause of injury and loss of independence in people over 65. This risk is dose-dependent but significant even at low doses in older patients.

Sedation stacking

Cannabis combined with gabapentin, pregabalin, opioids, or tricyclic antidepressants can dangerously amplify sedation and cognitive impairment. Older adults are especially vulnerable Strong evidence[9].

Cardiovascular effects of THC

THC causes transient increases in heart rate and blood pressure, relevant for PHN patients with coronary artery disease, arrhythmias, or hypertension Strong evidence[9].

Drug interactions with CBD

CBD inhibits CYP3A4 and CYP2C19, raising blood levels of many common drugs including gabapentin, amitriptyline, opioid metabolites, and warfarin Strong evidence[10]. The clinical significance of this in individual patients is not always predictable and requires monitoring.

Cannabinoid hyperemesis syndrome

Chronic heavy cannabis use can cause paradoxical severe nausea and vomiting Strong evidence[9].

Dependence and withdrawal

Regular daily cannabis use, especially THC-dominant products, can lead to physical and psychological dependence. Withdrawal symptoms (irritability, sleep disruption, anxiety) are mild compared to opioids but real Strong evidence[9].

Product quality and labeling

Unregulated CBD products are frequently mislabeled for potency and can contain contaminants (pesticides, heavy metals, microbial pathogens) Strong evidence[12]. This is less of a concern with prescription nabiximols (Sativex) but critical for over-the-counter products.

---

Harm-reduction approach if you decide to try cannabis:

  1. Tell your doctor, especially if you're on gabapentin, pregabalin, opioids, or amitriptyline.
  2. Start very low: 2.5 mg THC or a balanced THC:CBD preparation.
  3. Titrate slowly over days to weeks.
  4. Avoid alcohol and new sedatives.
  5. Reassess honestly after 2–4 weeks: Is pain actually reduced? Are side effects tolerable?
  6. If using a topical product, apply only to affected skin and avoid accidental systemic absorption.

⚠️ This article is not medical advice. It summarizes published evidence current as of October 2026. Decisions about treating PHN should be made with a clinician who knows your full medical history, current medications, and comorbidities.

Sources

  1. Book National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press.
  2. Peer-reviewed Nurmikko, T. J., et al. (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain, 133(1-3), 210-220.
  3. Peer-reviewed Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 3(3), CD012182.
  4. Peer-reviewed Abrams, D. I., et al. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology, 68(7), 515-521.
  5. Peer-reviewed Wilsey, B., et al. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain, 14(2), 136-148.
  6. Peer-reviewed Phan, N. Q., Siepmann, D., Gralow, I., & Ständer, S. (2010). Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. Journal der Deutschen Dermatologischen Gesellschaft, 8(2), 88-91.
  7. Peer-reviewed Smith, S. C., & Wagner, M. S. (2014). Clinical endocannabinoid deficiency (CECD) revisited; and Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate. Cannabis and Cannabinoid Research, 1(1), 44-46.
  8. Government Centers for Disease Control and Prevention. Shingles (Herpes Zoster): Clinical Overview and Prevention.
  9. Peer-reviewed Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219-2227.
  10. Peer-reviewed Brown, J. D., & Winterstein, A. G. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7), 989.
  11. Peer-reviewed Finnerup, N. B., et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology, 14(2), 162-173.
  12. Peer-reviewed Bonn-Miller, M. O., et al. (2017). Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 318(17), 1708-1709.

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 30, 2026
Fact-check pass — raised 10 flags
May 12, 2026
Fact-check pass — raised 3 flags
May 12, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.